Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935384 · ClinicalTrials.gov registry record
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
A clinical trial of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Guardant Health.
- Recruiting
- Registry status
- 470
- Enrollment target
- 1
- Study location
NCT05935384 is a study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Guardant Health. The registered enrollment target is 470 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05935384, a study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Guardant Health.
- RECRUITING
- Registry status
- 470 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1 and CT scan measurements.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Guardant360
Study Locations (1)
Illinois
- Orchard Healthcare Research Inc. - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2030-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05935384
The ClinicalTrials.gov registry entry for NCT05935384 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Guardant Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Guardant360 is the first listed.
NCT05935384 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05935384 about?
NCT05935384 is a clinical study titled "SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation". The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcom...
What is the current status of trial NCT05935384?
This trial is currently recruiting. The enrollment target is 470 participants. The study started on 2023-10-25. Estimated completion is 2030-12-30.
What conditions does trial NCT05935384 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer.
What interventions are being tested in trial NCT05935384?
The interventions under investigation include: Guardant360 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05935384?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05935384 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.